Sampatrilat (UK 81252, (S,S,S)‐N‐{1‐[2‐carboxy‐3‐(N‐mesyllysylamino)propyl]‐1‐cyclopentylcarbonyl}tyrosine) is a vasopeptidase or dual inhibitor of ACE and neutral endopeptidase with potential application in the treatment of hypertension and congestive heart failure. This evidence concerns the gene ACE and hypertensive disorder.